Low-Dose Lithium Supplementation Influences GSK3β Activity in a Brain Region Specific Manner in C57BL6 Male Mice
Journal of Alzheimer's Disease · 2023
DOI: 10.3233/jad-220813 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Alzheimer's Disease, 2023. Verfasst von Rachel K Fenech und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Sciences, Brock University, St. Catharines, ON, Canada. Hauptthemen laut MEDLINE: Alzheimer Disease, Drinking Water. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 49 Literaturangaben.
Abstract (Originalsprache)
Background
Lithium, a commonly used treatment for bipolar disorder, has been shown to have neuroprotective effects for other conditions including Alzheimer’s disease via the inhibition of the enzyme glycogen synthase kinase-3 (GSK3). However, dose-dependent adverse effects of lithium are well-documented, highlighting the need to determine if low doses of lithium can reliably reduce GSK3 activity.
Objective
The purpose of this study was to evaluate the effects of a low-dose lithium supplementation on GSK3 activity in the brain of an early, diet-induced Alzheimer’s disease model.
Methods
Male C57BL/6J mice were divided into either a 6-week or 12-week study. In the 6-week study, mice were fed a chow diet or a chow diet with lithium-supplemented drinking water (10 mg/kg/day) for 6 weeks. Alternatively, in the 12-week study, mice were fed a chow diet, a high-fat diet (HFD), or a HFD with lithium-supplemented drinking water for 12 weeks. Prefrontal cortex and hippocampal tissues were collected for analysis.
Results
Results demonstrated reduced GSK3 activity in the prefrontal cortex as early as 6 weeks of lithium supplementation, in the absence of inhibitory phosphorylation changes. Further, lithium supplementation in an obese model reduced prefrontal cortex GSK3 activity as well as improved insulin sensitivity.
Conclusion
Collectively, these data provide evidence for low-dose lithium supplementation to inhibit GSK3 activity in the brain. Moreover, these results indicate that GSK3 activity can be inhibited despite any changes in phosphorylation. These findings contribute to an overall greater understanding of low-dose lithium’s ability to influence GSK3 activity in the brain and its potential as an Alzheimer’s disease prophylactic.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Health Sciences, Brock University, St. Catharines, ON, Canada.
- Department of Kinesiology, Brock University, St. Catharines, ON, Canada.
- Centre for Neuroscience, Brock University, St Catharines, ON, Canada.
Zitieren
APA
Fenech, R. K., Hamstra, S. I., Finch, M. S., Ryan, C. R., Marko, D. M., Roy, B. D., Fajardo, V. A., & MacPherson, R. E. K. (2023). Low-Dose Lithium Supplementation Influences GSK3β Activity in a Brain Region Specific Manner in C57BL6 Male Mice. Journal of Alzheimer's Disease. https://doi.org/10.3233/jad-220813
Vancouver
Fenech RK, Hamstra SI, Finch MS, Ryan CR, Marko DM, Roy BD, et al. Low-Dose Lithium Supplementation Influences GSK3β Activity in a Brain Region Specific Manner in C57BL6 Male Mice. Journal of Alzheimer's Disease. 2023. doi:10.3233/jad-220813
BibTeX
@article{Fenech2023,
author = {Fenech, Rachel K and Hamstra, Sophie I and Finch, Michael S and Ryan, Chantal R and Marko, Daniel M and Roy, Brian D and Fajardo, Val A and MacPherson, Rebecca E K},
title = {Low-Dose Lithium Supplementation Influences GSK3β Activity in a Brain Region Specific Manner in C57BL6 Male Mice},
journal = {Journal of Alzheimer's Disease},
year = {2023},
doi = {10.3233/jad-220813}
}
EUVIMED